JOP20220038A1 - عوامل مضادة للملاريا - Google Patents

عوامل مضادة للملاريا

Info

Publication number
JOP20220038A1
JOP20220038A1 JOP/2022/0038A JOP20220038A JOP20220038A1 JO P20220038 A1 JOP20220038 A1 JO P20220038A1 JO P20220038 A JOP20220038 A JO P20220038A JO P20220038 A1 JOP20220038 A1 JO P20220038A1
Authority
JO
Jordan
Prior art keywords
plasmepsin
compounds
administration
treating
formula
Prior art date
Application number
JOP/2022/0038A
Other languages
English (en)
Inventor
F Cowman Alan
Favuzza Paola
Sleebs Brad
Hu Bin
A Mccauley John
K Thompson Jennifer
B Olsen David
Zhan Dongmei
Guo Zhuyan
Lei Zhiyu
Triglia Tony
Zhang Cailing
Zhao Lianyun
De Lera Ruiz Manuel
J Kelly Michael Iii
Original Assignee
Merck Sharp & Dohme
Msd Randd China Co Ltd
Walter & Eliza Hall Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Msd Randd China Co Ltd, Walter & Eliza Hall Inst Medical Res filed Critical Merck Sharp & Dohme
Publication of JOP20220038A1 publication Critical patent/JOP20220038A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوفر الاختراع الحالي طرق لعلاج الملاريا تشتمل على إعطاء مركبات الصيغة (I'): (I’) أو ملح منها مقبول صيدلانياً منها، لخاضع في حاجة إليها، حيث تكون المتغيرات كما يتم تعريفها في الطلب الحالي. يوفر الاختراع أيضاً استخدامات لمركبات الصيغة (I)، كما يتم تعريفها في الطلب الحالي، لتثبيط نشاط البلازميبسين X، البلازميبسين IX أو البلازميبسين X وIX، لعلاج عدوى ،البلازموديوم ولعلاج الملاريا. يتم أيضاً توفير طرق للعلاج تشتمل أيضًاعلى إعطاء مركب إضافي واحد أو أكثر مضاد للملاريا.
JOP/2022/0038A 2019-08-15 2020-07-21 عوامل مضادة للملاريا JOP20220038A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100781 WO2021026884A1 (en) 2019-08-15 2019-08-15 Antimalarial agents
PCT/CN2020/103178 WO2021027502A1 (en) 2019-08-15 2020-07-21 Antimalarial agents

Publications (1)

Publication Number Publication Date
JOP20220038A1 true JOP20220038A1 (ar) 2023-01-30

Family

ID=74570489

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0038A JOP20220038A1 (ar) 2019-08-15 2020-07-21 عوامل مضادة للملاريا

Country Status (20)

Country Link
US (1) US20220331321A1 (ar)
EP (1) EP4013742A4 (ar)
JP (1) JP7116859B2 (ar)
KR (1) KR20220047312A (ar)
CN (1) CN114555564B (ar)
AR (1) AR119784A1 (ar)
AU (1) AU2020328678B2 (ar)
BR (1) BR112022002692A2 (ar)
CA (1) CA3147665C (ar)
CL (1) CL2022000329A1 (ar)
CO (1) CO2022001342A2 (ar)
CR (1) CR20220067A (ar)
DO (1) DOP2022000037A (ar)
EC (1) ECSP22011746A (ar)
IL (1) IL290525A (ar)
JO (1) JOP20220038A1 (ar)
MX (1) MX2022001768A (ar)
TW (1) TW202115041A (ar)
UA (1) UA128074C2 (ar)
WO (2) WO2021026884A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CA3005809A1 (en) * 2015-11-25 2017-06-01 Ucb Biopharma Sprl Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors
EP3416647A4 (en) * 2016-02-18 2019-10-23 Merck Sharp & Dohme Corp. N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS
GB201603104D0 (en) * 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
GB201906804D0 (en) 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents

Also Published As

Publication number Publication date
JP7116859B2 (ja) 2022-08-10
UA128074C2 (uk) 2024-03-27
TW202115041A (zh) 2021-04-16
AU2020328678A1 (en) 2022-03-03
ECSP22011746A (es) 2023-01-31
KR20220047312A (ko) 2022-04-15
AR119784A1 (es) 2022-01-12
CL2022000329A1 (es) 2022-10-07
EP4013742A4 (en) 2023-07-12
AU2020328678B2 (en) 2023-02-02
CN114555564B (zh) 2024-01-30
IL290525A (en) 2022-04-01
CO2022001342A2 (es) 2022-05-20
MX2022001768A (es) 2022-06-09
DOP2022000037A (es) 2022-06-30
WO2021026884A1 (en) 2021-02-18
CR20220067A (es) 2022-04-20
EP4013742A1 (en) 2022-06-22
JP2022534454A (ja) 2022-07-29
CA3147665C (en) 2023-11-28
CA3147665A1 (en) 2021-02-18
BR112022002692A2 (pt) 2022-09-27
CN114555564A (zh) 2022-05-27
US20220331321A1 (en) 2022-10-20
WO2021027502A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
WO2017142825A3 (en) N3-substituted iminopyrimidinones as antimalarial agents
MX2023007192A (es) Inhibidores de prmt5.
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
TW200518758A (en) HIV replication inhibiting purine derivatives
NZ588217A (en) Spiro-indole derivatives for treating malaria, leishmaniasis and Chagas disease
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
MD3532459T2 (ro) Inhibitori ai LSD1 și utilizările medicale ale acestora
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
JOP20220038A1 (ar) عوامل مضادة للملاريا
MX2023007579A (es) Derivado de borato y usos del mismo.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2023003446A (es) Compuesto de pirimidina carboxamida y aplicación del mismo.